Valneva Scotland announces year-long support for local cancer charity Team Jak
The company’s workforce will volunteer and fundraise for Team Jak throughout the year
Read Moreby Emily Kimber | Oct 22, 2024 | News | 0
The company’s workforce will volunteer and fundraise for Team Jak throughout the year
Read Moreby Jen Brogan | Aug 2, 2024 | News | 0
Cancer is estimated to affect more than three million people living in the UK, according to Macmillan Cancer Support
Read Moreby Jen Brogan | Jul 17, 2024 | News | 0
The most globally prevalent cancers include breast, lung, bowel and prostate cancers
Read Moreby Jen Brogan | Jul 1, 2024 | News | 0
The biotech company will develop novel therapeutic drugs for the treatment of fatal diseases
Read Moreby Jen Brogan | Jun 17, 2024 | News | 0
Cancer was estimated to be responsible for more than 18 million cases worldwide in 2020
Read Moreby Jen Brogan | Jun 14, 2024 | News | 0
The installation will double the capacity of cancer genomic testing using robotic automation
Read Moreby Jen Brogan | May 31, 2024 | News | 0
The CVLP platform will speed up access to BioNTech and Genentech’s mRNA personalised cancer vaccines
Read Moreby Jen Brogan | May 8, 2024 | News | 0
The findings could potentially lead to new therapies and could stop the growth of cancers
Read Moreby Jen Brogan | Apr 8, 2024 | News | 0
Macmillan Cancer Support estimated that around three million people in the UK were living with cancer in 2022
Read Moreby Jen Brogan | Apr 2, 2024 | News | 0
The genetic condition affects one in 279 people in England and significantly increases cancer risk
Read Moreby Jen Brogan | Mar 28, 2024 | News | 0
The self-replicating mRNA molecule could be used in cancer and potentially a broad range of other diseases
Read Moreby Jen Brogan | Mar 8, 2024 | News | 0
The gamma treatment also shows potential for treating patients living with neurological diseases
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
